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Summary
Transforming growth factor (3 (TGF-)3) acts as a potent inhibitor of the growth and functions
of lymphoid and hemopoietic progenitor cells. Cell proliferation depends not only on the presence
of growth factors, but also on the development of specific receptor-signal transducing complexes.
We therefore investigated whether the inhibitory actions ofTGF-# could be mediated by inhibition
of growth factor receptors. TGF-(3 inhibited the constitutive level of interleukin 1 receptor (IIr
1R) expression on several murine lymphoid and myeloid progenitor cell lines, as well as IIAR
expression induced by interleukin 3 (IIr3) on normal murine and human bone marrow cells.
Furthermore, treatment of bone marrow progenitor cells with TGF-O concomitantly inhibited
the ability of IIA to promote high proliferative potential (HPP) colony formation as well as
blocked IL1-induced IIr2 productionby E14 6.1 cells. These findings provide the first evidence
that the inhibitory action of TGF-a on the growth and functional activities of hematopoietic
and T cells is associated with a reduction in the cell surface receptor expression for IIrl.
Transforming growth factor (3 (TGF-a) is a highly con-
served polypeptide, originally characterized by its ability
to induce the anchorage-independent growth of NRK 49F
fibroblasts in soft agar (1). Since then, TGF-0has been shown
to be multifunctional in its influence on cell growth. While
TGF-a acts as a growth factor for mesenchymal cells, os-
teoclasts, and Schwann cells, it is also a potent inhibitory signal
for a variety of other growth factor-driven biological func-
tions (2). We have shown that TGF-a is a selective negative
regulator of CSF-driven growth ofboth murine and human
immature hemopoietic cells (3-4). In particular, TGF-IQ in-
hibits the growth ofprimitive bone marrow progenitors such
as the high proliferative potential colony-forming cells (HPP-
CFC),t which develop in response to hemopoietin-1 (IL1)
plus CSFs (5). TGF-16 also affects other 11,1-driven biolog-
ical functions, including collagenase production by synovial
'Abbreviations used in thus paper. DSS, disuccinimidyl suberate; 5-FU,
5-fluorouracil; HPP-CFC, high proliferative potential colony-forming
cells.
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cells, thymocyte and lymphocyte proliferation, as well as chon-
drocyte activation (2, 6-8) .
TGF-0 may inhibit growth factors such as IIA at the level
of receptor expression. In this context, high affinity ILiR
have been detected on a variety of responsive cells, including
fibroblasts, keratinocytes, T cells, B cells, monocytes, and neu-
trophils (9-12) . Based on studies of cells transfected with a
cDNA encoding for IIr1R, it has been suggested that the
density of IL1R can regulate IIr1 action (13). We therefore
tested the effect of TGF-0 on the level of IL1R expressed
on murine lymphoid and myeloid progenitorcell lines. We
evaluated the effect of TGF-# on IIAR present on several
IL3-dependent early myeloid progenitor cell lines. Although
IL1R were not significantly detectable on freshly isolated
normal murine and humanbone marrow cells, treatment with
IL3 resulted in a significant upregulation ofreceptor expres-
sion. Treatment of these IL3-treated normal hemopoietic pro-
genitor cells, myeloid cell lines, as well as a T cell line with
physiological concentration ofTGF-/3 markedly reduced the
number ofIIARs and concomitantly resulted in a loss of re-
sponsiveness to IILl. These findings suggest that the inhibi-
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737-744tory action of TGF-(3 may be based on a reduction in cell
surface IL1R expression.
Materials and Methods
Animals.
￿
BALB/c mice were obtained from theanimal facility
of the NCI-Frederick Cancer Research Facility (Frederick, MD).
Cytokines.
￿
Bovine TGF-Owas purified to homogeneity using
a previously described procedure (14). Murine rIIr3 was obtained
from the supernatant of COS-7 cells transfected with 11,3 cDNA
usingapreviously described procedure (15).This supernatant does
not containother CSF activities as measured on factor-dependent
cell lines and the endotoxin level was found to be <0.038 ng/ml.
Human 11,3 wasobtained from ImmunexCorp. (Seattle, WA)and
human rIIrla was provided by P. Lomedico from Hoffmann-La
Roche, Nutley, NJ.
Cell Lines.
￿
The murine 11r3-dependent myeloid hemopoietic
celllinesFDC-P1,32D-c123,and32D-c113 were derived from long-
term bone marrow cultures (16, 17). NFS-60, NFS-58, andDA-3
were derived from thepreleukemic spleens from mice infected with
murine leukemia viruses (18). Thesecell lineshave thecharacteris-
tics of immature hemopoietic progenitors as determined by mor-
phology, cytochemistry, and cell surface marker expression. The
murine myeloid cell line FW311 was derived from fetal liver and
themurine myeloidcellline AC-2 wasprovided byJ. Garland.The
murine cell line E1,4 6.1, a variant subline of E1,4 thymoma cells
(19), was provided by H.R. MacDonald (Ludwig Institute for
Cancer Research, Basel, Switzerland). The murine T cell line
LBRM-33-1A4 was purchasedfrom American Type Culture Col-
lection (Rockville, MD).
Preparation ofIodinated ILIa.
￿
HumanrILlawaslabeled with
tall using chloramineT reagent as described previously (20). The
radiolabeled IIrla had a specific activity that ranged from 1 to 3
x 1011 cpm/mmol. There was no significant loss of biological ac-
tivity of the radiolabeled 11,1a as measured using the thymocyte
co-mitogenic activity assay.
Receptor Binding Assay.
￿
Afterthedifferent treatments, thecell
suspension waswashed once with cold medium and thecell pellet
was treated for 1 min on ice with 50 mM glycine-HCI (pH 3) to
remove possible endogenous IL1. Such treatment removes >95%
of the bound "I-11,1a. Subsequently, the cells were washed twice
with binding medium (RPMI 1% BSA supplemented with 0.1%
sodium azide and 10 mM Hepes) and incubated at 4°C with 500
pM tall-labeled human I1r1a in a final volume of 0.2 ml. After
2-3 h incubation at 4°C, cell-bound radioactivity was separated
from unbound I'll-11,1a by centrifugation ofthe sample through
a mixture of 1.5:1 (vol/vol) dibutyl phthalate/bis(2-ethylhexyl)-
phthalate (Eastman Kodak Co., Rochester, NY). Nonspecific
bindingwas determined by incubating thecells with labeled II'Ica
in the presence of 50-fold excess of unlabeled ligand.
Affinity Cross-linking.
￿
After a 1-h incubation with 1251-ILl at
4°C, the cells were washed once in cross-linking buffer (PBS, 10
MM MgCl2, pH 8.3) and incubated for 30 min at 4°C with con-
stant rotation in 1 ml of cross-linking buffer containing 100 Ftg
disuccinimidyl suberate (DSS; Pierce Chemical Co., Rockford, IL).
Receptor-bound ligands were cross-linked using 100 fig/ml DSS
androtated at 4°Cfor 30 min. After two washes in TRIS buffer,
5 x 1(16 cells were solubilized for 30 min at 4°C in lysis buffer
(20 mmol/L Tris-HCI, pH 7.4, 50 mmol/liter NaCl, 0.5% NP-
40, 0.5% sodium deoxycholate, 4 mmol/liter iodoacetic acid, 5
mmol/liter sodium pyrophosphate, 5 mmol/liter sodium fluoride
and 1 mmol/liter PMSF). Lysates were centrifuged at 10,000 g for
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10 min to remove nuclei and other debris. The protein content
ofeach sample was determined using acommercially available kit
(BioRadProtein Assay; BioRad Laboratories, Richmond, CA), and
samples containing equal amounts of proteins were run under
reducing conditionon 7-15% SDS-PAGE. Affinity labeled protein
was detected by autoradiography of the dried gels.
HPPColony Formation.
￿
Thebone marrow cells were aspirated
from the femur of BALB/c mice injected 5 d previously with 5-
fluororacil (5-FU; LyphoMed Inc., Rosemont, IL) at 150 mg/kg
and plated into a double-layer agar culture system as previously
described (21). After 14 d ofincubation, HPP-CFCthat represent
colonies >0.5 mm in diameter were scored using a dissecting mi-
croscope.
11,2 Production andAssay.
￿
E146.1 cells were cultured at 2 x
105 cells/ml for 24 h with or without various agents. IL2 activity
in the supernatants was quantitated by their abilityto support the
growth of the IIr2-dependent murine CTLIr2 cells as previously
described (22). Units of 11,2 were analyzed using the PROBIT
program.
Results
Dose-and Time-dependent EfectofTGRO on NFS-60 Cells.
Using 1251-IIrlCi, we found that three of the seven IL3-
dependent myeloidprogenitor cell linestested, namely NFS-
60, NFS-58, and AC-2, were positive for IIAR expression
(ratio of specific/nonspecific binding, >1) (Table 1). We used
the I1r1R+ cell line NFS-60 to study the effect of TGF-/3
on IIAR expression in detail. When NFS-60 cells maintained
in IL3 were treated for 24 h with increasing concentrations
of TGF-a, we observed a dose-dependent reduction in IL1R
Table 1.
￿
IL-1R Expression on Murine Hemopoietic
Progenitor Cell Lines
Factor-dependent cell lines were maintained in RPMI medium con-
taining 20% WEHI-3 conditioned medium.
t The specific binding was determined by subtracting the number of
counts per minute bound in the presence of 50-fold excess IL-la.
Each point represent the mean ± SEM of two or more determina-
tions. In our assay, the ratio of specific/nonspecific binding >1 was
statistically shown to reflect the presence of a detectable and mea-
surable number of receptors.
Cell lines'
Specific
bindingt
cpm
Ratio
NFS-60 1,202 ± 203 4.2
NFS-58 1,653 ± 263 3.8
AC-2 1,605 ± 47 4.8
DA-3 153 ± 7 <1
FW311 <50 <1
FDC-P1 <50 <1
32D-c113 <50 <1
32D-c123 198 ± 23 <1A
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expression with an ED5o of 0.2 ng/ml (10-11 M) and a max-
imal effect at 20 ng/ml (Fig. 1 A), concentrations that are
within the physiological range (2). Kinetic studies revealed
that >50% inhibition of TGF-,3 action occurred within 6 h
and maximal effect (>90%) was observed at 24 h (Fig. 1 B).
The inhibitory effect of TGF-(3 was not due to a direct com-
petition of TGF-(3 for IL
I
binding sites on the cell surface.
As much as 250 ng/ml (10- e M) of unlabeled TGF-# in our
binding assay did not complete with the binding of radiola-
beled ILla (data not shown) . Moreover, high cell viability
was maintained as determined by trypan blue exclusion.
Selective Effect of TGF-a on Cell Surface Protein Expres-
sion. To determine whether the inhibition of IL1R expres-
sion by TGF-((3 reflects a general decrease in cell surface pro-
tein, we tested the effect of TGF-a on a variety of murine
myeloid cell surface antigens. Data from cytofluorometric anal-
ysis indicated that the addition of TGF-i0 to NFS-60 cells
under culture conditions resulting in maximal inhibition of
IIr1R (24 h, 20 ng/ml) did not affect the expression of any
of the five cell surface antigens tested (data not shown) . These
included Thy-1.2 (T cells and progenitor cells), Ly-5 (pan leu-
kocyte), Mac-1 (granulocytes and macrophages), RBC-8C5
(granulocytes), and LY17 (Fc receptor).
Equilibrium Binding of1151-ILIa to NFS-60 Cells.
￿
To de-
termine whether the reduction in
ILI
binding was due to
a decrease in the number of ILIR, NFS-60 cells maintained
in IL3 were incubated for 24 h with or without TGF-0. The
cells were washed, treated with glycine-HCI, and then in-
cubated at 4°C with increasing concentrations of 1251-ILla.
A plot ofspecific counts bound, as a function of radio ligand
concentration (Fig. 2 A), indicated that binding was dose
dependent and saturable. Pretreatment with TGF-a almost
completely abolished the subsequent specific binding of la-
beled
ILI
without any noticeable effect on the nonspecific
binding component (Fig. 2 B) . Data from Scatchard analysis
(Fig. 2 C) revealed one class of IIAR on NFS-60 cells with
an average of 400 receptors per cell and an affinity of 1.0 ±
0.2 x 10-1° M. Treatment with TGF-O decreased the
number of IL1R to <50 per cell without any significant
reduction in affinity (Kd = 1.3 ± .4 x 10 -1o M). The de-
crease in the number of receptors per cell was consistently
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Time Course
Figure 1.
￿
Kinetics and dose-dependent effect of
TGF-fl on IL1R expression. NFS-60 cells were in-
cubated 24 h with or without increasing concen-
trations of TGF-,B (A) or with a constant dose of
TGFO_ ' __a
￿
TGF-,B (20 ng/ml) for different periods of time
(B). At the end of the incubation, the samples
were processed as described in the Materials and
Methods. Each point represents the mean of
duplicate determination.
observed in all experiments (n = 6). These results demon-
strated that the inhibition of 1251-ILI binding to TGF-0-
treated NFS-60 cells is related to a net decrease in MAR number
rather than reduced receptor affinity.
Contribution ofEndogenous ILI Production in the Inhibition
ofILlR Expression by TGF0. Since TGF-O can induce the
expression of
ILI
mRNA in human monocytes (23), the in-
hibition of 1251-IL1a binding on TGF-a-treated progenitor
cells might be due to the occupancy and internalization of
the receptor by endogenously produced ILl. To assess this
possibility, we tested the ability of the conditioned medium
of NFS-60 cells, treated with TGF-a for 24 h, to compete
with 1251-ILla in an IL1 receptor assay. Using LBRM-33-
lA4 as a cellular source of high affinity IL1R, we could not
detect any competitive binding by TGF-a-treated NFS-60
cells supernatants down to a receptor detection limit of 60
pM ILI (Fig. 3). These data suggested that TGF-((3 was not
inducing the production of ILI by the myeloid cells. LPS,
a potent ILI induer, also failed to induce the production
of detectable
ILI
binding activity by NFS-60 cells. Addition-
ally, TGF-a did not change the level or rate of ILIR inter-
nalization by labeled ILla (data not shown).
Affinity Cross-linking of 1251-IL-1 a to Controland TGF-0-
treated Cells. Affinity labeling of the hemopoietic progen-
itor cell lines NFS-60 and AC-2, which were maintained in
IL3, with 1251-IL1 followed by cross-linking revealed one
sharp band of -65-70 kD (Fig. 4). This band was ablated
by addition of 50-fold excess of unlabeled IL1, and thus
represents an ILI binding protein on NFS-60 and AC-2 cells.
Pretreatment of the cells for 24 h with TGF-iO resulted in
a marked inhibition of the 65-70-kD IL
I
binding protein
on NFS-60 and AC-2 cells (Fig. 4) .
Induction ofIL1R Expression on Murine and Human Bone
Marrow Cells by 11,3. Using 1251-IL-la, we found that
normal unstimulated murine and human bone marrow cells
do not show significant binding of radiolabeled ILl. How-
ever, 24-48 h incubation with IL3, a T lymphocyte derived
growth factor for hemopoietic progenitorcells (24), resulted
in a significant increase in ILI binding (Table 2).
Cross-linking data indicated that murine bone marrow cells
displayed a faint but identical band of 65-70 kD, whose in-0
c
Figure 2.
￿
Comparison of 125I-ILla dose-response binding to con-
trol and TGF-S-treated NFS-60. The cells were incubated 24 h in
(A) the absence or (B) presence of 20 ng/ml TGF-(3. At the end of
the incubation, the cells were processed as described in the Materials
and Methods. 125I_IILla binding was determined by adding various
concentrations of labeled IIA alone (open circle) or in the presence of
50-fold excess of unlabeled 1Lla (open square). (C) Scatchard analysis
of equilibrium binding of 1251_II.1 to control or TGF-S-treated cells.
Each point is derived from the mean of duplicate determinations
from which nonspecific binding was subtracted. Scatchard data were
analyzed using the LIGAND program.
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Figure 3.
￿
Role of endogenous 11A in TGF-0 inhibition of ILl
receptor. NFS-60 cells were incubated for 24 h in the presence or ab-
sence of TGF-0 (20 ng/ml) or LPS (2 Kg/ml) and then the superna-
tants were tested for IIA competitive activity in a radioreceptor assay
using LBRM-33-1A4 cells.
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tensity was markedly increased when the bone marrow cells
were treated for 24 h with IL3 . The same autoradiogram
revealed an additional inhibitable 180-kD band on IL3-treated
bone marrow cells, but the significance of this component
is not clear. The 65-70 kD band was also detected on bone
marrow cells treated with 5-FU, an anticycling drug that is
cytotoxic for actively cycling progenitors but does not affect
the slowly cycling immature progenitors. Pretreatment with
TGF-0 for 24 h inhibited IM binding capacity of 5-FU-
treated bone marrow cells and prevented the increase in ILl
binding induced by IL3 on normal bone marrow cells. These
data support the hypothesis that TGF-0 inhibits IIAR ex-
pression on early normal bone marrow progenitor cells.
Effect ofTGRO on ILIR Expression ~ a T Cell Line.
￿
To
determine whether the effect of TGF-
￿
on progenitor cells
could be applied to other cell types, we performed similar
cross-linking experiments using EL4, a murine thymoma cell
line. As previously reported, labeled II*1 binds predominantly
to a 78-85-kD protein on this cell type (Fig. 4) (25, 26).
Twenty-four hours ofpretreatment with TGF-0 also inhibited
the majority of ILl binding protein on the T cell line (Fig. 4).
Biological Effect of TGF--S on ILI-induced Biological Activi-
ties. We next evaluated the relationship of the inhibition
of IIAR expression on bone marrow and E14 cells to the
biological effects of ILI. First, using the soft agar colony
formation assay and IIr3 as a co-stimulator, we observed that
the addition of TGF-0 abrogated the effect of IM on HPP-
CFC colony formation (Table 2). These results show that
TGF-0 inhibits the effect of IM on the growth of progen-
itor enriched 5-FU-treated murine bone marrow cells along
with the reduction of IL1R expression. We also evaluated
the effect of TGF-0 on IL-1-induced 11,2 production in the
murine cell line, EL4 6 .1 C10. As already reported, this T
cell line produces a detectable amount of 11,2 when stimu-
lated with IL1 alone (27). Our data indicates that pretreat-
ment with TGF-0 for 8-12 h inhibited the ability of IL1
alone or in combination with calcium ionophore to induce
11,2 production by E1,4 6.1 cells (Table 3).
Discussion
Several laboratories have demonstrated that TGF-fi nega-
tively regulates the growth of murine and human hemato-
poietic cells in vitro and in vivo (3-5, 28-30) . In addition,
we have shown that TGF-0 selectively inhibits the growth
of primitive hematopoietic progenitors (CFU, granulocytes
[G], erythroid [E], megakaryocytes [M], macrophages [M]
[CPU-GEMM] and HPP), while more committed progen-
itors (CFU-G, CFU-M, and CFU-E) are insensitive (3, 4).
IIA is known to be biochemically identical to hemopoietin-1
and has positive effects on hemopoiesis in promoting the
growth and survival of early progenitor cells (31-32). Since
HPP progenitor cells require IM and CSFs to proliferate and
differentiate in vitro and are inhibited by TGF-A (5), we asked
whether one potential mechanism of TGF-0 action might
be at the levelofILl receptor expression. Using cross-linking
technology we found that IIAR expression is markedly in-
hibited on I1,3-treated and 5-FU-treated bone marrow cells.Figure 4.
￿
Affinity labeling of IIAR on control and TGF-0-treated cells . IIAce binding proteins were detected as described in Materials and
Methods. For this assay, the cells were incubated with 2.5 nM of 1251-labeled ILla alone (-) or in the presence (+) of 125 nM IL-la.
However, the expression ofIL1R in normal and 5-FU-treated
bone marrow is not sufficient to allow accurate equilibrium
binding studies. Thus, we identified several IL1R+ murine
hematopoietic progenitor cell lines representative ofimma-
ture hematopoietic cells, blocked in differentiation. Treatment
of these progenitor cell lines with TGF-a markedly inhibited
IL1R expression without a general inhibition of cell surface
protein expression, suggesting that one mechanism ofgrowth
inhibition might be related to the decrease in the number
of cell surface IL1R .
Since ILA has been reported to inhibit the expression of
Table 2 .
￿
IL-1R Expression on Murine and Human
" Murine bone marrow cells were obtained as described in Material
and Methods. The cells were incubated 24 h with or without mu-
rine IL-1 used at 20 ng/ml. Human bone marrow cells were ob-
tained from healthy donors and the mononuclear cells were isolated
by centrifugation on Ficoll-Hypaque gradient . The cells were in-
cubated 48 h in the presence or absence of 10 ng/ml human IL-3 .
t The specific binding and ratio was determined as described at the
legend of Table 1.
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receptors for ILA through the internalization of the receptor-
ligand complex (33), we tested whether induction of ILl
by TGF-0 was responsible for the reduction in IL1R . The
supernatant from TGF-/3-treated NFS-60 cells failed to com-
pete for radiolabeled ILl in binding assays. Thus, in contrast
to data reported for mature monocytes (23), the early my-
eloid cell lines do not produce IL1 or "IL1-like" binding
activities in response to TGF-/3 . These data suggest thatTGF-0
acts 4irectly to inhibit the expression of IL1R . Whether
TGF-0 inhibits ILlR expression at the level of transcription
will be investigated using a cDNA probe for IL1R (25) .
Two different classes of antigenically and biochemically dis-
tinct ILA receptors have been identified by different laborato-
ries (34-35) . By affinity cross-linking, the molecular weight
of theTCR (EL4) is 87 kD, whereas the B cell receptor (70Z/3
cells) is 66 kD (35) . The presence of a B cell-type IL1R has
also been reported on a mature bone marrow-derived granulo-
cytic population (33) . In our experiments, affinity labeling
and cross-linking showed that TGF-0 inhibited a65-70-kD
ILloi binding protein on freshly aspirated progenitor cells
(5-FU-treated) and on the progenitor cell lines. Based on the
molecular weight of the ILiR present on progenitor cells,
our data suggest that these progenitor cells expressed the B
cell-type receptor. In addition, TGF-0 also inhibited the 80-85-
kD protein expressed on T cells. Thus, TGF-0 inhibits both
classes of IL1R.
On normal bonemarrow cells, IL-3 treatment upregulates
two different molecular mass IL1 binding proteins (65-70
kD, 180 kD), both of which are inhibitable when TGF-0
is present in the assay. These results indicate that TGF-0 can
inhibit the induction by IL3 of IL1R in vitro. Recent data
from our laboratory indicate that TGF-0 can also similarly
inhibit IL1R expression induced in vivo on bone marrow
cells (manuscript in preparation), which supports the pro-
Hemopoietic Bone Marrow Cells
Specific
Cell source' Factor binding# Ratio
cpm
Murine bone marrow cells none 153 ± 17 <1
Human bone marrow cells none <50 <1
Murine bone marrow cells IL-3 1,102 ± 92 2.3
Human bone marrow cells IL-3 529 ± 16 2.5Table 3.
￿
Effect of TGF# on IL-1 Activity
Types of assay
HPP-type colony formation`
IL-1 production#
' The HPP colony formation assay was performed as described in Material and Methods. For this assay, 20 ng/ml of TGF-/3 was added to the
cultures, human recombinant IL-la was used at the indicated doses and murine recombinant IL-3 was used at 20 ng/ml.
t The IL-2 production assay was performed as previously described (21) using EL-4 6.1 C10 cells, an IL-1-responsive murine thyoma cell line.
For this assay, human IL-la was used at 30 pg/ml, and calcium ionophore (A23187) was used at 5 x 10-6 M. Units of IL-2 were analyzed
using the PROBIT program.
posed role for TGF-0 as a negative regulator of hemopoietic
cell growth in vivo. In this regard, the inhibition of IL1-de-
pendent hematopoiesis by TGF-0 may ultimately result in
a depletion of macrophages and other marrow-derived inflam-
matory cells, since we find (unpublished observation) that
the bone marrow ofTGF-/3-treated mice becomes hypoplastic.
It has been postulated that the mechanism regulating IL1
responsiveness is related to IL1R expression. This is supported
by experiments showing that IL1 induction ofprostaglandins
and CSFs by CHO cells that express low numbers of IL1R
is increased by transfection with cDNA encoding for IL1R
(13). Additionally, treatment offibroblasts with platelet-derived
growth factor increased the number of IL1R together with
the capacity of the cellsto proliferate in response to ILl (36).
The results presented here demonstrate that TGF-/3 inhibits
HPP colony formation together with an inhibition of ILlR
expression. Since HPP cells also require IL3 and CSF-1 in
addition to RA for continued growth, it is possible that the
growth inhibitory effect of TGF-0 may also involve inhibi-
tion of receptors for the CSFs. In addition, it is possible that
the downregulation of IL1R occurs secondarily to inhibi-
tion of cell growth/colony formation. However, we consider
this unlikely since 50% ofthe IL1R downmodulation occurs
within 6-8 h, reaching a maximum at 24 h which precedes
any observed effect on cell growth (usually detectable within
3-5 d). In fact, recent data from our laboratory indicate that
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expression of CSF receptors was also inhibited by TGF-0
(manuscript in preparation). Thus the diminution of cell sur-
face ILlR on progenitor cells represents a model for the mech-
anism of growth inhibition by TGF-0 that could possibly
be extended to other cell surface receptors.
IL2 productionby the T cell line EL4 6.1 induced by IL1
alone is inhibited by pretreatment with TGF-(3, which argues
for a direct relationship between IL1R inhibition and T cell
function. Thus, TGF-0 may block IL1-driven T cell activa-
tion, by inhibiting cell surface IL1R expression. Our findings
that TGF-0 inhibits IL1R expression on T cells provides a
basisfor the proposed immunosuppressive role for this cytokine
(37) that can blockIA-driven T cell-dependent B cell reac-
tions and thymocyte proliferation.
TGF-0 has been proposed to be a pro-inflammatory agent,
basedon its ability to chemoattract peripheral monocytes and
to induce IL1 mRNA expression (23). On the other hand,
TGF-0 reduces the production of H202 by already activated
macrophages (38). Even though injections ofTGF-0 induce
a mononuclear cell infiltrate and edema, TGF-a, unlike IL1,
does not induce any erythema as in classical inflammation.
Our data can reconcile these apparently contradictory obser-
vations since the inhibition of IL1R expression by TGF-0
renders the cells unresponsive to IL1 thus providing a mech-
anism by which TGF-0 minimizes inflammatory responses
and promotes the repair process.
We thank Dr. JeffRossio for IL2determinations and Dr. Dan Longo for helpful advice on the manuscript.
Stimulators Without TGF-0
Colonies/5 x
With TGF
10' bone marrow cells
Medium 0 0
IL-1 2 ng 0 0
IL-1 20 ng 0 0
IL-3 2 ± 0.7 0
IL-1 2 ng + IL-3 12.5 ± 1.1 0
IL-1 20 ng + IL-3 17.5 ± 0.4 0
U/ml
Medium 0 0
IL-1 81 0
Ionophore 0 0
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